Biomea Fusion - BMEA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 259.20 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.96
▼ -0.2 (-2.79%)

This chart shows the closing price for BMEA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biomea Fusion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMEA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMEA

Analyst Price Target is $25.00
▲ +259.20% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $25.00, with a high forecast of $37.00 and a low forecast of $16.00. The average price target represents a 259.20% upside from the last price of $6.96.

This chart shows the closing price for BMEA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Biomea Fusion.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2022EF Hutton Acquisition Co. ILower TargetBuy$27.00 ➝ $22.00Low
11/1/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$27.00Low
10/31/2022HC WainwrightBoost TargetBuy$16.00 ➝ $37.00Low
8/2/2022HC WainwrightReiterated RatingBuy$16.00Low
6/2/2022HC WainwrightReiterated RatingBuy$16.00High
5/27/2022Piper SandlerLower Target$25.00 ➝ $16.00Low
5/17/2022Piper SandlerLower Target$27.00 ➝ $25.00Low
1/12/2022HC WainwrightInitiated CoverageBuy$13.00High
12/16/2021OppenheimerInitiated CoverageOutperformHigh
5/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Medium
5/11/2021Piper SandlerInitiated CoverageOverweight$27.00High
5/11/2021Jefferies Financial GroupInitiated CoverageBuy$26.00High
(Data available from 12/4/2017 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
5/8/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/6/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/5/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
11/4/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Biomea Fusion logo
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $6.96
Low: $6.88
High: $7.13

50 Day Range

MA: $9.05
Low: $6.96
High: $11.60

52 Week Range

Now: $6.96
Low: $2.84
High: $14.20

Volume

67,539 shs

Average Volume

75,117 shs

Market Capitalization

$204.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biomea Fusion?

The following equities research analysts have issued reports on Biomea Fusion in the last year: EF Hutton Acquisition Co. I, HC Wainwright, Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for BMEA.

What is the current price target for Biomea Fusion?

3 Wall Street analysts have set twelve-month price targets for Biomea Fusion in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 259.2%. HC Wainwright has the highest price target set, predicting BMEA will reach $37.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $16.00 for Biomea Fusion in the next year.
View the latest price targets for BMEA.

What is the current consensus analyst rating for Biomea Fusion?

Biomea Fusion currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMEA will outperform the market and that investors should add to their positions of Biomea Fusion.
View the latest ratings for BMEA.

What other companies compete with Biomea Fusion?

Other companies that are similar to Biomea Fusion include Immutep, InterCure, Kamada, AC Immune and Puma Biotechnology. Learn More about companies similar to Biomea Fusion.

How do I contact Biomea Fusion's investor relations team?

The company's listed phone number is 650-980-9099 and its investor relations email address is [email protected] The official website for Biomea Fusion is www.biomeafusion.com. Learn More about contacing Biomea Fusion investor relations.